Personal Finance

Why HP, Booking Holdings, and Novavax Slumped Today

Black printer with color-printed page in the output bin.

Thursday was a down day on Wall Street, but declines in major market benchmarks were relatively modest. The Dow Jones Industrial Average finished off about 69 points, while other indexes made similar percentage moves lower. Market participants didn't have a particularly strong response to general news, preferring instead to concentrate on impacts to specific companies and their shares. HP (NYSE: HPQ) , Booking Holdings (NASDAQ: BKNG) , and Novavax (NASDAQ: NVAX) were among the worst performers. Here's why they did so poorly.

HP slides on sluggish sales

Shares of HP dropped 17% after the hardware company reported its fiscal first-quarter financial results. The tech giant said that revenue was higher by just 1% compared to the year-earlier period, and it took a substantial decline in outstanding share count to produce an 8% rise in earnings per share. HP's personal systems unit got some support from the commercial sector, and printing saw some bright spots in sales of printer hardware. Yet HP's outlook was tepid at best, and the fact that customers are turning to e-commerce sources for consumables like printer ink is likely to have a permanent negative impact on the printer giant's long-term business prospects.

Black printer with color-printed page in the output bin.

Image source: HP.

Booking's guidance disappoints

Booking Holdings suffered an 11% fall in its share price following its release of its fourth-quarter financial report. The online travel specialist posted impressive results for the period, including revenue growth of 15% and bottom-line gains of 25% compared to year-earlier levels. Yet what sent some investors into a panic was Booking's guidance for the first quarter of 2019, which included flat expectations for revenue and gross travel bookings. The travel company has a history of providing guidance that proved lower than eventual results, but shareholders aren't willing to bet on that continuing to be the case today.

Novavax misses the mark

Finally, shares of Novavax plunged 67% . The vaccine maker announced poor results from the phase 3 clinical trial of its ResVax vaccine for respiratory syncytial virus, saying that the vaccine failed to meet the primary objective of preventing medically significant lower respiratory tract infection as a result of the disease. Novavax CEO Stanley Erck tried to salvage what he could from the trial, noting that "while this study did not meet the pre-specified success criterion for the primary clinical endpoint of this trial, the data indicate that ResVax protects infants from some of the most serious consequences of RSV," including respiratory tract infection hospitalizations and cases involving sever hypoxemia. Nevertheless, shareholders think that this could make ResVax a non-starter for future sales, and they've reassessed the stock's valuation as a consequence.

Offer from The Motley Fool: The 10 best stocks to buy now

Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has quadrupled the S&P 500!*

Tom and David just revealed their ten top stock picks for investors to buy right now.

Click here to get access to the full list!

* Stock Advisor returns as of Jan. 31, 2019.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Booking Holdings. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BKNG NVAX HPQ

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More